BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 24901123)

  • 1. Research on the epigenetic modification of pancreatic cancer vaccine.
    Cao W; Zhou G; Qiu J; Xu L; Ding X; Zhang H; Zhou X
    Hepatogastroenterology; 2014; 61(130):272-7. PubMed ID: 24901123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetically modified pancreatic carcinoma PANC-1 cells can act as cancer vaccine to enhance antitumor immune response in mice.
    Tao Y; Lin F; Li T; Xie J; Shen C; Zhu Z
    Oncol Res; 2013; 21(6):307-16. PubMed ID: 25198660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Constitutive expression of CIITA directs CD4 T cells to produce Th2 cytokines in the thymus.
    Patel DR; Li W; Park JS; Sofi MH; Gourley TS; Hangoc G; Kaplan MH; Chang CH
    Cell Immunol; 2005 Jan; 233(1):30-40. PubMed ID: 15876426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile.
    Hu HM; Urba WJ; Fox BA
    J Immunol; 1998 Sep; 161(6):3033-41. PubMed ID: 9743368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination gene therapy with CD86 and the MHC class II transactivator in the control of lung tumor growth.
    Martin BK; Frelinger JG; Ting JP
    J Immunol; 1999 Jun; 162(11):6663-70. PubMed ID: 10352284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer.
    Yamamoto M; Kamigaki T; Yamashita K; Hori Y; Hasegawa H; Kuroda D; Moriyama H; Nagata M; Ku Y; Kuroda Y
    Oncol Rep; 2009 Aug; 22(2):337-43. PubMed ID: 19578774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapeutic effects of treatment of pancreatic carcinoma by interleukin-23 and apoptotic cell antigen-modified dendritic cell vaccine: experiment with mice].
    Tan G; Wang ZY; Yin S
    Zhonghua Yi Xue Za Zhi; 2006 Apr; 86(14):943-6. PubMed ID: 16759530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic targeting in pancreatic cancer.
    van Kampen JG; Marijnissen-van Zanten MA; Simmer F; van der Graaf WT; Ligtenberg MJ; Nagtegaal ID
    Cancer Treat Rev; 2014 Jun; 40(5):656-64. PubMed ID: 24433955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.
    Mortara L; Castellani P; Meazza R; Tosi G; De Lerma Barbaro A; Procopio FA; Comes A; Zardi L; Ferrini S; Accolla RS
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3435-43. PubMed ID: 16740768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Murine dendritic cells pulsed with an anti-idiotype antibody induce antigen-specific protective antitumor immunity.
    Saha A; Chatterjee SK; Foon KA; Primus FJ; Bhattacharya-Chatterjee M
    Cancer Res; 2003 Jun; 63(11):2844-54. PubMed ID: 12782590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines.
    Schnurr M; Galambos P; Scholz C; Then F; Dauer M; Endres S; Eigler A
    Cancer Res; 2001 Sep; 61(17):6445-50. PubMed ID: 11522639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-gamma-induced HLA-DR expression in colorectal and gastric cancer cells.
    Satoh A; Toyota M; Ikeda H; Morimoto Y; Akino K; Mita H; Suzuki H; Sasaki Y; Kanaseki T; Takamura Y; Soejima H; Urano T; Yanagihara K; Endo T; Hinoda Y; Fujita M; Hosokawa M; Sato N; Tokino T; Imai K
    Oncogene; 2004 Nov; 23(55):8876-86. PubMed ID: 15467734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Remodeling epigenetic modifications at tumor suppressor gene promoters with bovine oocyte extract.
    Wang Z; Yue Y; Han P; Sa R; Ren X; Wang J; Bai H; Yu H
    Cytotherapy; 2013 Sep; 15(9):1164-73. PubMed ID: 23800731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-1 beta inhibits IFN-gamma-induced class II MHC expression by suppressing transcription of the class II transactivator gene.
    Rohn W; Tang LP; Dong Y; Benveniste EN
    J Immunol; 1999 Jan; 162(2):886-96. PubMed ID: 9916712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA methylation of TH1/TH2 cytokine genes affects sensitization and progress of experimental asthma.
    Brand S; Kesper DA; Teich R; Kilic-Niebergall E; Pinkenburg O; Bothur E; Lohoff M; Garn H; Pfefferle PI; Renz H
    J Allergy Clin Immunol; 2012 Jun; 129(6):1602-10.e6. PubMed ID: 22277202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent anti-tumor-preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions.
    Mortara L; Frangione V; Castellani P; De Lerma Barbaro A; Accolla RS
    Int Immunol; 2009 Jun; 21(6):655-65. PubMed ID: 19395374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-mediated down-regulation of MHC class II in DC development is attributable to the epigenetic control of the CIITA type I promoter.
    Choi YE; Yu HN; Yoon CH; Bae YS
    Eur J Immunol; 2009 Mar; 39(3):858-68. PubMed ID: 19224634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Change in gene expression profiles of secreted frizzled-related proteins (SFRPs) by sodium butyrate in gastric cancers: induction of promoter demethylation and histone modification causing inhibition of Wnt signaling.
    Shin H; Kim JH; Lee YS; Lee YC
    Int J Oncol; 2012 May; 40(5):1533-42. PubMed ID: 22246241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain.
    Thompson JA; Dissanayake SK; Ksander BR; Knutson KL; Disis ML; Ostrand-Rosenberg S
    Cancer Res; 2006 Jan; 66(2):1147-54. PubMed ID: 16424052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.